Moxidectin

Caitlin Soto, PharmD, BCIDP, Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Treatment of onchocerciasis due to Onchocerca volvulus in patients aged 4 years and older and weighing at least 13 kg
    • Access Data FDA
  • It is not routinely commercially available in the U.S.

GLOBAL AND EMERGING USES

GLOBAL AND EMERGING USES

GLOBAL AND EMERGING USES

  • Alternative therapy for the management of Strongyloides stercoralis infection.
  • Investigational/emerging therapy for Trichuris trichiura, principally in combination with albendazole; efficacy has varied considerably among studies and geographic settings.
  • Globally, ivermectin remains the established backbone of onchocerciasis MDA; WHO still describes ivermectin-based population treatment as the current core strategy. World Health Organization
    • Moxidectin was added to the 2025 WHO Model Lists of Essential Medicines and Essential Medicines for Children as a therapeutic alternative to ivermectin for onchocerciasis and lymphatic filariasis. Iris
    • Broader WHO guidance on alternative treatment strategies remains under development; WHO currently lists that guideline for 2027 Q2. World Health Organization
  • Global access remains limited and is not yet analogous to the mature ivermectin donation/MDA infrastructure

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.